Drugs / BL0175
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07366632 | Jan → May 2026 overdue | — | Shanghai Best-Link Bioscience, LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06738966 | Mar 2025 → Feb 2026 overdue | breast cancer, endometrial cancer, ovarian cancer | Shanghai Best-Link Bioscience, LLC | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07658183 | Jul 2026 → Oct 2027 expected | Her2-receptor negative breast cancer | Shanghai Best-Link Bioscience, LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL0175 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06738966 ↗ |
| Action | Inhibit | “an estrogen receptor down regulator” NCT06738966 ↗ |
| Modality | Other / unclassified | “BL0175 is a polymer-drug conjugate, composed of a steroidal estrogen receptor antagonist fulvestrant covalently linked to a PEG-modified poly- polymer via a peptide based...” NCT07366632 ↗ |